HSBC Holdings’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,944
| Closed | -$239K | – | 2925 |
|
|
2026
Q1 | $239K | Buy |
+5,944
| New | +$128K | ﹤0.01% | 2540 |
|
|
2025
Q4 | – | Sell |
-15,025
| Closed | -$345K | – | 2921 |
|
|
2025
Q3 | $345K | Sell |
15,025
-42,873
| -74% | -$1000K | ﹤0.01% | 2277 |
|
|
2025
Q2 | $1M | Buy |
57,898
+32,899
| +132% | +$609K | ﹤0.01% | 1798 |
|
|
2025
Q1 | $552K | Sell |
24,999
-102,829
| -80% | -$2.84M | ﹤0.01% | 2024 |
|
|
2024
Q4 | $4.08M | Buy |
127,828
+9,341
| +8% | +$281K | ﹤0.01% | 1209 |
|
|
2024
Q3 | $3.41M | Buy |
118,487
+83,563
| +239% | +$3.09M | ﹤0.01% | 1241 |
|
|
2024
Q2 | $1.34M | Sell |
34,924
-63,626
| -65% | -$2.88M | ﹤0.01% | 1548 |
|
|
2024
Q1 | $5.79M | Buy |
+98,550
| New | +$6.28M | ﹤0.01% | 1052 |
|
|
2023
Q4 | – | Sell |
-50,544
| Closed | -$1.96M | – | 2716 |
|
|
2023
Q3 | $1.96M | Buy |
+50,544
| New | +$2.22M | ﹤0.01% | 1459 |
|
|
2023
Q2 | – | Sell |
-17,530
| Closed | -$1.17M | – | 2557 |
|
|
2023
Q1 | $1.17M | Buy |
+17,530
| New | +$1.01M | ﹤0.01% | 1704 |
|
|
2022
Q3 | – | Sell |
-10,887
| Closed | -$497K | – | 2919 |
|
|
2022
Q2 | $497K | Buy |
10,887
+996
| +10% | +$45.4K | ﹤0.01% | 2337 |
|
|
2022
Q1 | $504K | Buy |
9,891
+5,290
| +115% | +$234K | ﹤0.01% | 2415 |
|
|
2021
Q4 | $219K | Buy |
+4,601
| New | +$181K | ﹤0.01% | 2988 |
|
|
2021
Q3 | – | Sell |
-3,701
| Closed | -$236K | – | 2974 |
|
|
2021
Q2 | $236K | Buy |
+3,701
| New | +$191K | ﹤0.01% | 2671 |
|
|
2020
Q3 | – | Sell |
-7,580
| Closed | -$248K | – | 2714 |
|
|
2020
Q2 | $248K | Buy |
+7,580
| New | +$243K | ﹤0.01% | 2225 |
|
Other funds holding APLS
HSBC Holdings's APLS Position: Q2 2026 in Review
HSBC Holdings sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,944 shares — an estimated $239K sold.
HSBC Holdings first reported a position in APLS in Q2 2020 and held it in 15 quarters. The position peaked at $5.79M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- HSBC Holdings reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- HSBC Holdings sold 5,944 Apellis Pharmaceuticals shares in Q2 2026, an estimated $239K.
- HSBC Holdings first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 15 quarters.
- HSBC Holdings's Apellis Pharmaceuticals position peaked at $5.79M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.